Redeye returns with a more optimistic outlook following Polygiene’s Q3 2025 report, which presented mixed figures but confirmed our expectations of a recovery in Q4 ’25. We make smaller positive estimate adjustments while our valuation range remains intact. We argue that the macro effects are transitory, staying positive to the long-term case which trades at an attractive valuation.
LÄS MER
